Lilly I8G-MC-LMDC

Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer’s Disease (PERISCOPE)

What is the Periscope Study?

Subjects with mild Alzheimer’s disease will receive the study drug, LY3303560 or placebo given intravenously for 76 weeks. Study visits are approximately once every 4 weeks and consist of cognitive assessments, laboratory procedures, and administration of study medication.

What is the Purpose of Periscope?

The Periscope study aims to assess the efficacy and safety of the investigational medication, LY3303560, in mild Alzheimer's disease. LY3303560 is thought to help remove tau protein from the brain. Tau protein tangles are believed to be a leading component to the progression of Alzheimer's Disease.

Eligibility

Men and women ages 60-85 years old with a diagnosis of mild Alzheimer's Disease. There are other eligibility criteria you must meet in order to participate.

Organization
Butler Hospital

Area of Study
Memory and Aging

Status
Closed